Cargando…

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922311/ https://www.ncbi.nlm.nih.gov/pubmed/35300120 http://dx.doi.org/10.2147/COPD.S363875

Ejemplares similares

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
por: Price, David B, et al.
Publicado: (2022)

Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
por: Skloot, Gwen S., et al.
Publicado: (2023)

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
por: Dean, James, et al.
Publicado: (2020)

Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma
por: Ming, Simon Wan Yau, et al.
Publicado: (2019)

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022)

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016)

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
por: Voorham, Jaco, et al.
Publicado: (2020)

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients
por: Price, David, et al.
Publicado: (2013)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status [Corrigendum]
Publicado: (2019)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting [Corrigendum]
Publicado: (2017)

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes [Corrigendum]
Publicado: (2019)

Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry [Corrigendum]
Publicado: (2021)

Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study [Corrigendum]
Publicado: (2020)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

2-Bromobeclometasone dipropionate
por: Ketuly, Kamal Aziz, et al.
Publicado: (2009)

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study
por: Usmani, Omar S., et al.
Publicado: (2021)

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study
por: Gessner, Christian, et al.
Publicado: (2022)

High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
por: Corradi, Massimo, et al.
Publicado: (2016)

COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]
Publicado: (2014)

CORRIGENDUM to Image Statistics and the Fine Lines of Material Perception
Publicado: (2016)

Corrigendum to “Recommendations for Diagnosis and Management of Osteoporosis in COPD Men”
por: Mazokopakis, Elias E., et al.
Publicado: (2017)

Corrigendum to “Particle Radiation-Induced Nontargeted Effects in Bone-Marrow-Derived Endothelial Progenitor Cells”
por: Sasi, Sharath P., et al.
Publicado: (2016)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE [Corrigendum]
Publicado: (2016)

Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study
por: Bakakos, Petros, et al.
Publicado: (2022)

A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices
por: van der Palen, Job, et al.
Publicado: (2017)

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]
Publicado: (2019)

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]
Publicado: (2019)

Nasal high-flow in acute hypercapnic exacerbation of COPD [Corrigendum]
Publicado: (2019)

Repetitive Saliva Swallowing Test Predicts COPD Exacerbation [Corrigendum]
Publicado: (2021)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
por: Gao, Jinming, et al.
Publicado: (2015)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study
por: Martin, Richard J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1km0e4poc1746jv1lt3d1gh5op